AntiCD40L (TDI 28)

The immune system plays a crucial role in certain aspects of ALS disease progression. This compound tamps down the immune system by blocking CD40 positive antigen presenting cells from becoming activated macrophage.

Status

Type: Biologic
Stage: Active
Status: Active
Sponsor: ALS Therpy Development Institute & Anelixis

TDI Says:

Thanks to Ice Bucket Challenge donations, we were able to invest $1.5 million into this program to pay for the manufacturing of 10,000 units of this compound necessary for IND enabling studies and trials through Phase 2B.

Learn More

Published Results

Comment on this Topic

(All comments are moderated before they appear here.)